Publications by authors named "M Bednarikova"
Article Synopsis
- - The phase 3 study ENGOT-cx11/GOG-3047/KEYNOTE-A18 found that adding pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival in patients with advanced cervical cancer during the first interim analysis.
- - In this study, 1060 patients with high-risk cervical cancer were randomly assigned to receive either pembrolizumab or a placebo alongside chemoradiotherapy, with treatment outcomes evaluated at the second interim analysis.
- - The primary outcomes measured were progression-free survival and overall survival, focusing on patient mortality, with safety being a secondary consideration.
Article Synopsis
- The text provides a detailed overview of surgical treatment options for recurrent gynecological cancers, specifically focusing on malignancies affecting the ovaries, fallopian tubes, uterus, cervix, vagina, and vulva, excluding breast cancers.
- It emphasizes the importance of a multidisciplinary approach when determining the best surgical treatment, taking into account various individual prognostic factors.
- The decision-making process for treatment should involve discussions among a specialized oncogynecological commission to tailor strategies to each patient's unique situation.
(1) Background: Adolescents who are under the care of child and youth institutions are vulnerable due to factors that can include disruption to family structure or education and adverse experiences. They often experience poor or unstable support systems, leaving them at risk of delinquency. In this context, sports engagement may provide a stable structure and have positive effects in this population.
View Article and Find Full Text PDFObjective: To report long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or complete remission (CR) following chemotherapy.
Methods: Analysis of the prespecified, exploratory subgroup of patients with TP53wt EC from the phase 3 SIENDO study was performed. Progression-free survival (PFS) benefit in patients with TP53wt EC and across other patient subgroups were exploratory endpoints.
High-grade serous carcinoma of the ovary, fallopian tube and peritoneum (HGSC), the most common type of ovarian cancer, ranks among the deadliest malignancies. Many HGSC patients have excess fluid in the peritoneum called ascites. Ascites is a tumour microenvironment (TME) containing various cells, proteins and extracellular vesicles (EVs).
View Article and Find Full Text PDF